ZZ Biotech Announces First Patients Dosed in Phase 2 Clinical Trial of 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Houston, TX December 2, 2021 — ZZ Biotech, a clinical stage biopharmaceutical company developing the experimental drug 3K3A-APC for some of the biggest unmet needs in stroke, neurodegenerative disease and chronic wound healing, today announced that the first patients have been dosed in a Phase 2 clinical trial evaluating 3K3A-APC for the treatment of amyotrophic…

Read More